Literature DB >> 9622072

Activation of p73 silent allele in lung cancer.

M Mai1, A Yokomizo, C Qian, P Yang, D J Tindall, D I Smith, W Liu.   

Abstract

p73, a first p53 relative, has recently been identified and demonstrated to be monoallelically expressed. This protein shows significant amino acid sequence and functional similarities to p53. However, it is unclear whether this protein functions as a tumor suppressor. To elucidate the role of p73 in tumor development, we investigated the expression of the p73 gene in lung cancer. In a comparison between normal lung and tumor tissues, p73 was more highly expressed in tumors. Moreover, using a C/T polymorphism in exon 2 for allele-specific expression analysis in 21 pairs of lung tumors and matched normal tissues, we found that five heterozygous samples exclusively expressed both alleles in tumors while showing monoallelic expression in matched normal tissues. This result was confirmed by single-nucleotide primer extension analysis. Mutation analysis of all 13 coding exons of the gene in 21 lung tumor DNAs revealed several polymorphisms, but no tumor-specific mutations were detected. These findings strongly suggest that p73 may play an important role in lung tumorigenesis through activation of a silent allele and overexpression of wild-type p73 rather than as a tumor suppressor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9622072

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

Review 1.  Genomic imprinting: implications for human disease.

Authors:  J G Falls; D J Pulford; A A Wylie; R L Jirtle
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

2.  The human p73 promoter: characterization and identification of functional E2F binding sites.

Authors:  Ratnam S Seelan; Meredith Irwin; Petra van der Stoop; Chiping Qian; William G Kaelin; Wanguo Liu
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

3.  p73 G4C14 to A4T14 polymorphism is associated with colorectal cancer risk and survival.

Authors:  Kyung-Eun Lee; Young-Seoub Hong; Byoung-Gwon Kim; Na-Young Kim; Kyoung-Mu Lee; Jong-Young Kwak; Mee-Sook Roh
Journal:  World J Gastroenterol       Date:  2010-09-21       Impact factor: 5.742

4.  Association of a p73 exon 2 GC/AT polymorphism with colorectal cancer risk and survival in Tunisian patients.

Authors:  Amira Toumi Arfaoui; Lilia Ben Mahmoud Kriaa; Olfa El Amine El Hadj; Majid A Ben Hmida; Myriam Khiari; T Khalfallah; Lasaad Gharbi; Sabeh Mzabi; Sadaa Bouraoui
Journal:  Virchows Arch       Date:  2010-07-20       Impact factor: 4.064

5.  Chediak-Higashi syndrome with early developmental delay resulting from paternal heterodisomy of chromosome 1.

Authors:  Irini Manoli; Gretchen Golas; Wendy Westbroek; Thierry Vilboux; Thomas C Markello; Wendy Introne; Dawn Maynard; Ben Pederson; Ekaterini Tsilou; Michael B Jordan; P Suzanne Hart; James G White; William A Gahl; Marjan Huizing
Journal:  Am J Med Genet A       Date:  2010-06       Impact factor: 2.802

6.  E1B 55-kilodalton oncoproteins of adenovirus types 5 and 12 inactivate and relocalize p53, but not p51 or p73, and cooperate with E4orf6 proteins to destabilize p53.

Authors:  S Wienzek; J Roth; M Dobbelstein
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

7.  Association of p73 G4C14-A4T14 polymorphisms with genetic susceptibilities to breast cancer: a case-control study.

Authors:  Xin Zhou; Chengyi Wu
Journal:  Med Oncol       Date:  2012-04-26       Impact factor: 3.064

8.  Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of hepatocellular carcinoma in a Chinese population.

Authors:  Benyuan Deng; Fei Liu; Yonggang Wei; Limei Luo; Xi Chen; Lvnan Yan; Bo Li
Journal:  Tumour Biol       Date:  2012-10-12

9.  p73 G4C14-to-A4T14 polymorphisms are positively correlated with triple-negative breast cancer in southwestern China.

Authors:  Xin Zhou
Journal:  Med Oncol       Date:  2013-02-27       Impact factor: 3.064

10.  p73alpha is a candidate effector in the p53 independent apoptosis pathway of cisplatin damaged primary murine colonocytes.

Authors:  A Oniscu; N Sphyris; R G Morris; S Bader; D J Harrison
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.